Idiopathic Pulmonary Fibrosis (IPF) research hub
9 indexed studies · 3 currently recruiting
- ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
This study is testing a new tablet, called NAL ER, to see if it can help reduce coughing in people with Idiopathic Pulmonary Fibrosis (IPF). Researchers want to find out if it is safe and if different doses work better than a dummy pill (placebo).
Germany · Netherlands · Italy - ongoing, recruitingPhase II and Phase III (Integrated)
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
This study is looking at a new medicine called bexotegrast for idiopathic pulmonary fibrosis (IPF). It aims to see if the medicine can help improve lung function and slow down the disease, and if it's safe to use. Some participants will receive the medicine, and others a dummy pill.
Greece · France · Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough
This study looks at a new medicine called BI 1839100. It's for people with lung conditions like Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) who have a troublesome cough. We want to see if the medicine can reduce coughing and if it's safe to use.
Belgium · Czechia · Poland - recruitingPHASE2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
This study is for people who were in a previous study with an inhaled medicine called AP01 for lung scarring (pulmonary fibrosis). It’s an extension to see how the medicine works over a longer time, using an inhaler twice a day.
United States · Australia · Canada - active not recruitingPHASE2
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
This study, called ASPIRE, is testing a new medication, Buloxibutid, for Idiopathic Pulmonary Fibrosis (IPF). It compares the new drug to a dummy pill (placebo) to see if it's safe and helps improve lung function over 52 weeks.
United States · Argentina · Australia - recruitingPHASE2
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
This study is testing a new inhaled medicine, LTI-03, for Idiopathic Pulmonary Fibrosis (IPF). It aims to see if LTI-03 is safe, helps with lung scarring, and improves IPF symptoms.
United States · Australia · Poland - recruiting
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
This study looks at how anti-fibrotic medicines for lung scarring might affect your body shape, specifically your muscle and fat. It uses simple tests like body scanners and muscle scans to see if these medicines cause changes not picked up by just weighing yourself.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases
This study looks at a new scanning method to find areas of scarring in people with certain long-term inflammatory conditions like Crohn's, ulcerative colitis, and some lung diseases. We want to see how this scan relates to markers in the body and help doctors understand these diseases better.
Netherlands - authorisedTherapeutic exploratory (Phase II)
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis
This study is testing a new medicine called zampilimab for idiopathic pulmonary fibrosis (IPF). It aims to see if two different doses of zampilimab are safe and work better than a dummy medicine over 24 weeks, with an optional longer period.
Belgium · Germany · Italy